First, diagnostically, it should be regarded as a potentially systemic disease from inception, with pathologists encouraged to extensively sample specimens and clinicians interpreting HER2‐positive MPD‐DCIS diagnoses in this setting with extreme caution. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.